Chemistry:Elisrasib

From HandWiki

Elisrasib is an investigational new drug that is being developed by D3 Bio for the treatment of solid tumors. It is a G12C mutant selective KRAS inhibitor.[1][2][3][4]

References

  1. ↑ "Elisrasib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800068960. 
  2. ↑ "D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities". Cancer Discovery 14 (9): 1675–1698. September 2024. doi:10.1158/2159-8290.CD-24-0006. PMID 38717075. 
  3. ↑ "Next-generation KRAS-G12C inhibitor D3S-001 shows promise". Nature Reviews. Clinical Oncology 22 (7): 459. July 2025. doi:10.1038/s41571-025-01028-8. PMID 40346420. 
  4. ↑ "Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC". Cancer Discovery 16 (6): OF1. June 2026. doi:10.1158/2159-8290.CD-NW2026-0041. PMID 42010749. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Elisrasib&oldid=4583952"